Cary Lin saw an opportunity to make sustainability truly accessible when even big, innovative companies were falling short. Common Heir was born out of this vision. Cary believes in our collective power to make change and her quest to preserve beauty in the world. She joins Susanne Mitschke, Co-Founder & CEO of Citruslabs to discuss why the clean beauty industry needs to embrace scientific evidence to back their products. 

In this episode, Susanne and Cary discuss

Why Common Heir ran a clinical study before launching their clean beauty products
How more and more brands are setting the standard for enrolling their products in clinical trials
Is a clinical study worth the investment? Which types of brands benefit most from clinical trials 
How Cary decided on the various aspects of her clinical trial (participant inclusion criteria, exclusion criteria, etc.)
Why Cary went the extra mile with expert skin grading 
The difference between a consumer perception study and a clinical trial
What’s next for Common Heir?


About Common Heir
Common Heir is a clean, luxury skincare brand that launched in 2021. Although they’re new to the game, they’ve been working with Citruslabs from the beginning in order to create high-powered skincare that meets their standards for product performance. 
To learn more about Citruslabs or to discuss how to begin testing your wellness product, visit citruslabs.com and contact us!
Send us your questions and we'll answer them in a future episode. Email us at [email protected].

Ver todos los episodios